Researchers unveiled antibody–bottlebrush prodrug conjugates that overcome payload potency and stability limitations of conventional antibody–drug conjugates (ADCs). This modular synthesis allows high drug-to-antibody ratios and incorporation of lower potency drugs, enhancing targeted cancer therapy effectiveness while maintaining favorable pharmacological profiles in preclinical models. These innovations promise to broaden the payload repertoire and improve therapeutic outcomes in oncology.